Systematic review and meta-analysis: Placebo rates in induction and maintenance trials of ulcerative colitis

Journal of Crohn's and Colitis

Volumn 10, Issue 5, 2016, Pages 607-618

  Jairath, Vipul ^a,b,c   Zou, Guangyong ^b,c   Parker, Claire E ^b,c   Macdonald, John K ^b,c   Mosli, Mahmoud H ^b,c,d   Khanna, Reena ^b,c   Shackelton, Lisa M ^b   Vandervoort, Margaret K ^b   AlAmeel, Turki ^e   Al Beshir, Mohammad ^e   AlMadi, Majid ^f   Al Taweel, Talal ^g   Atkinson, Nathan S S ^a   Biswas, Sujata ^a   Chapman, Thomas P ^a   Dulai, Parambir S ^b,h   Glaire, Mark A ⁱ   Hoekman, Daniel ^j   Koutsoumpas, Andreas ^a   Minas, Elizabeth ^k   Samaan, Mark A ^l   Travis, Simon ^a   D'Haens, Geert ^b,j   Levesque, Barrett G ^b,h   Sandborn, William J ^b,h   Feagan, Brian G ^b,c   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

^f KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^g MUBARAK AL KABEER HOSPITAL   (Kuwait)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^l GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

DAI; Disease Activity Index; Mayo Clinic Score; MCS; Randomised controlled trial; RCT; UC; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; BIOLOGICAL PRODUCT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; ANTIINFLAMMATORY AGENT;

ARTICLE; CLINICAL FEATURE; COCHRANE LIBRARY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; EMBASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK ASSESSMENT; STUDY DESIGN; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; METHODOLOGY; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MODELS, STATISTICAL; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84982218415     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw004     Document Type: Article

References (71)

1. Sedgwick P. Treatment effects and placebo effects. BMJ 2015;350:h267.
2. Enck P, Bingel U, Schedlowski M, et al. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 2013;12:191-204.
3. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008;336:999-1003.
4. Enck P, Klosterhalfen S, Weimer K, et al. The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci 2011;366:1889-95.
5. Su C, Lewis JD, Goldberg B, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007;132:516-26.
6. Sutherland LR, Martin F, Greer S. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-8.
7. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomised study. N Engl J Med 1987;317:1625-9.
8. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
9. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-73.
10. Ilnyckyj A, Shanahan F, Anton PA, et al. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997;112:1854-8.
11. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
12. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
13. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63.
14. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001;20:641-54.
15. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 1995;48:45-57; discussion 59-60.
16. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Software 2010;36:1-48.
17. Team RC. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2012. Open access available at: http://cran. r-project.org2014.
18. Higgins J, Altman D, Sterne J. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions: Version 5.1.0 [Updated March 2011]. Hoboken, NJ: Wiley-Blackwell, 2011.
19. Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab [anti-CD20] in active ulcerative colitis. Gut 2011;60:1520-6.
20. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
21. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507.
22. Feagan BG, McDonald J, Greenberg G, et al. An ascending dose trial of a humanized A4 B7 antibody in ulcerative colitis [UC]. Gastroenterology 2000;118:A874.
23. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7.
24. Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor [CD25], for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006;55:1568-74.
25. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002.
26. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65 e1-3.
27. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab [rhuMAb beta7] in moderate to severe ulcerative colitis. Gut 2013;62:1122-30.
28. Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014;384:309-18.
29. Mayer L, Sandborn WJ, Stepanov Y, et al. Anti-IP-10 antibody [BMS-936557] for ulcerative colitis: a phase II randomised study. Gut 2014;63:442-50.
30. Sands BE, Sandborn WJ, Creed TJ, et al. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology 2012;143:356-64 e1.
31. Danese S, Rudzinski J, Brandt W, et al. Tralokinumab for moderate-tosevere UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 2015;64:243-9.
32. Vermeire S, Ghosh S, Panes J, et al. The mucosal address in cell adhesion molecule antibody PF-00547, 659 in ulcerative colitis: a randomised study. Gut 2011;60:1068-75.
33. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-tosevere ulcerative colitis. Gastroenterology 2014;146:85-95; quiz e14-5.
34. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132:66-75; quiz 432-3.
35. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once-or twicedaily MMX mesalamine [SPD476] for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5:95-102.
36. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa [mesalazine] is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54:960-5.
37. Scherl EJ, Pruitt R, Gordon GL, et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomised, double-blind, placebo-controlled study. Am J Gastroenterol 2009;104:1452-9.
38. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine [Asacol] for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 1991;115:350-5.
39. Sutherland LR, Martin F. 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci 1987;32:64S-66S.
40. Sutherland LR, Onstad M, Peppercorn G, Greenberger M, N. Goodman N M. A double-blind placebo controlled, multicentre study of the efficacy and safety of 5-aminosalicylic acid tables in the treatment of ulcerative colitis. Can J Gastroenterol 1990;4:463-7.
41. Watanabe M, Nishino H, Sameshima Y, et al. Randomised clinical trial: Evaluation of the efficacy of mesalazine [mesalamine] suppositories in patients with ulcerative colitis and active rectal inflammation-A placebocontrolled study. Aliment Pharmacol Ther 2013;38:264-73.
42. Beeken W, Howard D, Bigelow J, et al. Controlled trial of 4-ASA in ulcerative colitis. Dig Dis Sci 1997;42:354-8.
43. Williams CN, Haber G, Aquino JA. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories. Dig Dis Sci 1987;32:71S-75S.
44. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014;63:433-41.
45. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomised controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013;145:149-57 e2.
46. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX[R] extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012;143:1218-26 e1-2.
47. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomised placebo-controlled trial. Gastroenterology 2008;134:688-95.
48. Schreiber S, Keshavarzian A, Isaacs KL, et al. A randomised, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 2007;132:76-86.
49. van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004;53:1646-51.
50. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomised, Israeli multicenter trial. Gastroenterology 1996;110:1416-21.
51. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429-35.
52. Nikolaus S, Rutgeerts P, Fedorak R, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003;52:1286-90.
53. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus [FK506] therapy in refractory ulcerative colitis. Gut 2006;55:1255-62.
54. Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus [FK506] in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012;18:803-8.
55. Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012;143:62-9 e4.
56. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-24.
57. Sandborn WJ, Sands BE, Wolf DC, et al. Repifermin [keratinocyte growth factor-2] for the treatment of active ulcerative colitis: a randomised, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003;17:1355-64.
58. Steinhart AH, Hiruki T, Brzezinski A, et al. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 1996;10:729-36.
59. Sandborn W, Bosworth B, Zakko S, et al. Efficacy and safety of budesonide foam for inducing remission in mildly to moderately active ulcerative proctitis or ulcerative proctosigmoiditis. Inflamm Bowel Dis 2013;19:S83.
60. Sandborn W, Bosworth B, Zakko S, et al. Budesonide foam for inducing remission in active mild-to-moderate ulcerative proctitis or ulcerative proctosigmoiditis: Results of two randomised, placebo-controlled trials. Am J Gastroenterol 2013;108:S542.
61. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96-109 e1.
62. Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine [Rowasa] suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000;95:1749-54.
63. Lichtenstein GR, Gordon GL, Zakko S, et al. Clinical trial: oncedaily mesalamine granules for maintenance of remission of ulcerative colitis-a 6-month placebo-controlled trial. Aliment Pharmacol Ther 2010;32:990-9.
64. Dieppe P. Trial designs and exploration of the placebo response. Complement Ther Med 2013;21:105-8.
65. Sandborn W, Feagan BG, Wolf DC, et al. The TOUCHSTONE Study: a Randomised, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator [RPC1063] in Moderate to Severe Ulcerative Colitis. Gastrointest Endosc 2015;5:AB147.
66. Vermeire S, Sandborn W, Danese S, et al. TURANDOT: a randomised, multicentre double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 [PF] in patients with moderate to severe ulcerative colitis [UC]. J Crohns Colitis 2015;9:S13.
67. Rief W, Nestoriuc Y, Weiss S, et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 2009;118:1-8.
68. Schmid CH, Cappelleri JC, Lau J. Bayesian methods to improve sample size approximations. Methods Enzymol 2004;383:406-27.
69. Rutherford BR, Sneed JR, Roose SP. Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom 2009;78:172-81.
70. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309:1351-5.
71. van Deventer SJ, Wedel MK, Baker BF, et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006;23:1415-25.